Vimta Labs Limited — Investor Meet, 25-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Vimta Labs hits record Q1 FY'26 revenue of INR 99.3 Cr, surging 31.4% YoY. EBITDA grew 33.1% to INR 35.4 Cr, maintaining strong 35.7% margins. PAT jumped 35.9% to INR 18.9 Cr. The company is debt-free.

Growth is driven by pharma testing and research, with an encouraging clinical trial pipeline and successful US FDA & EMA audits. They're expanding into biologics CR&D (Q1 FY'27 launch) and adding 200,000 sq ft of lab space. A 1:1 bonus issue was approved. Management expects continued positive demand, aiming for INR 120-125 Cr quarterly revenue, even with potential minor margin shifts due to new facility costs.